NDATOPICALLOTION
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CUTIVATE (fluticasone propionate) by Sandoz is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0. Approved for asthma, chronic obstructive pulmonary disease, allergic rhinitis. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CUTIVATE (fluticasone propionate) is a topical corticosteroid lotion approved in 2005 for treating inflammatory skin conditions responsive to corticosteroids. The precise mechanism of action involves modulation of signaling, immune function, inflammation, and protein regulation, though the exact pathway remains incompletely understood. It is applied directly to affected skin areas.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential workforce consolidation and transition planning within the brand team.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0.005% in corticosteroid-responsive dermatoses is unknown.
Indications (3)
Worked on CUTIVATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.